ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0238

The Impact of Preeclampsia on Pregnancies and Infants of Women with Rheumatic Disease

Megan Milne1, Megan Clowse2, Amanda Eudy1, Congwen Zhao1 and Ben Goldstein1, 1Duke University, Durham, NC, 2Duke University, Chapel Hill, NC

Meeting: ACR Convergence 2021

Keywords: Preeclampsia, pregnancy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Rheumatic diseases, such as SLE, are associated with serious maternal, pregnancy, and infant complications. The role that preeclampsia plays in these outcomes in women with SLE and other rheumatic disease remains unclear. We compared pregnancy and infant outcomes among women with SLE and other rheumatic diseases with and without preeclampsia in a single academic center.

Methods: Deliveries in women with rheumatic disease were identified from both a prospective cohort of women with rheumatic disease who received care within a university rheumatology clinic and a chart-reviewed list of deliveries to women with an ICD-9/10 code for SLE. Mothers with rheumatic disease were matched with their infants through the electronic medical record (EMR) to allow data extraction. Preeclampsia was determined by the obstetric team at the time of delivery and collected through chart review. Pregnancy and infant outcomes were compared between those with and without preeclampsia.

Results: 263 singleton deliveries were included in the study of whom 14% had preeclampsia. Preeclampsia was significantly more common among women with SLE than with other rheumatic diseases (SLE 27% vs other rheumatic diagnoses 8%, p< 0.001); this pattern persisted among both Black and White women and women with private health insurance. Among women with SLE, however, the rate of preeclampsia was similar between Black and White women and those with and without private insurance. Having preeclampsia increased the mother’s hospital stay for delivery by an average of 2 days for women with SLE and 1 day for women with other rheumatic diseases.

Infants born to preeclamptic mothers were delivered an average of 3.3-weeks earlier than those without preeclampsia; they were 4-times more likely to be born preterm (55.3% vs 14.5%, p< 0.001), a difference that persisted in mothers with SLE and other rheumatic diagnoses. More than twice as many infants born to preeclamptic mothers were admitted to the neonatal intensive care unit (NICU; 36.8% vs 15.1%, p< 0.0001). While infants born to women with SLE without preeclampsia had modestly higher rates of preterm birth and NICU admission compared to women with other rheumatic diseases, preeclampsia drove these rates significantly higher in all women.

Conclusion: Preeclampsia has important health consequences on mothers with rheumatic disease, including increasing hospitalization at delivery by 1-2 days, and on the infant, increasing the frequency of preterm delivery and NICU admission. Preeclampsia was particularly common among women with SLE in this cohort. These data suggest that preventing preeclampsia could have a dramatic impact on the short- and long-term health of women with rheumatic disease and their children.

Maternal characteristics of patients with autoimmune disease and comorbid preeclampsia compared to patients with autoimmune disease without preeclampsia

Infant Outcomes of children born to patients with autoimmune disease and comorbid preeclampsia compared to patients with rheumatic disease without preeclampsia


Disclosures: M. Milne, None; M. Clowse, UCB Pharma, 2, Pfizer, 5, GSK, 2, 5; A. Eudy, NIH NCATS Award Number 1KL2TR002554, 5, Pfizer, 5, Exagen, 5; C. Zhao, None; B. Goldstein, None.

To cite this abstract in AMA style:

Milne M, Clowse M, Eudy A, Zhao C, Goldstein B. The Impact of Preeclampsia on Pregnancies and Infants of Women with Rheumatic Disease [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/the-impact-of-preeclampsia-on-pregnancies-and-infants-of-women-with-rheumatic-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-preeclampsia-on-pregnancies-and-infants-of-women-with-rheumatic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology